skeeter
04-20-2006, 02:26 PM
I got this information from a older mexican dude.. He worked in landscaping for years, and told me to take the trim, bud, and let it soak in alchol for a few days, and shake it like hell everyday.. After, a few days start rubbing the mix on your body..The longer it sits, the better it works...
I know some of you can do search somewhere, and see this is something thant has been around for thousands of years..
This really helps with pain, or it does with me..
Better yet, just mix it like your making keif, but with pure rubbing alchol.. It's got to work by opening up the skin pores, and let the thc & other compounds soak into your skin..IMO... I hope this helps...There has to be a place to read about this pain med...
I hope this helps, and I hope you might try it for pain...
skeets
c-ray
04-22-2006, 12:12 PM
United States Patent 6,949,582
Wallace
September 27, 2005
Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
Abstract A method of relieving analgesia and reducing inflammation using a cannabinoid delivery topical liniment composition containing from about 97.5% to about 99.5% by weight a 70% monohydric alcohol solution, and from about 0.5% to about 2.5% by weight of a synergistic cannabinoid mixture extracted from the female plant Cannabis sativa L, including in combination: 9-Tetrahydrocannabinol (delta-9-THC), 9-THC Propyl Analogue (THC-V), Cannabidiol (CBD), Cannabidiol Propyl Analogue (CBD-V), Cannabinol (CBN), Cannabichromene (CBC), Cannabichromene Propyl Analogue (CBC-V), Cannabigerol (CBG), terpenoids, and flavonoids. The liniment is applied topically, preferably by spraying, and the constituents of the mixture are absorbed through the skin and interact with cannabinoid receptors in the body and tissues of a human patient to produce therapeutic analgesic and anti-inflammatory effects without undesirable psychotropic side effects.
Inventors: Wallace; Walter H. (P.O. Box 5262, Katy, TX 77491) Appl. No.: 243059 Filed: September 13, 2002 Current U.S. Class: 514/454; 514/456; 514/731; 514/733 Intern'l Class: A61K 031/35; A61K 031/05 Field of Search: 514/454,456,731,733
References Cited [Referenced By] U.S. Patent Documents 4464378Aug., 1984Hussain.
Other References
Formukong et al, Inflammation, 12 (4), 1988, 361-371.
Meng I et al, Nature, 395, 1998, 381-383.
Richardson J et al, IASP Newsletter, 75, 1998m 111-119.
Calignanao A et al,, Nature, 394, 1998, 277-281.
Malfait A et al, Proceedings Natl. Acad. Sci., 9561, Aug. 2000.
Touitou, E et al, International J. Pharmaceutics, 43, 1988, 9-15.
Bond, J et al, J. Invest. Dermatol., Jun. 1988, 90 (6) 810-3.
Morimoto, Y et al, J. Invest Dermatol., Aug. 1992, 44 (8), 634-9.
Sato, K et al, J. Pharm. Sci., Feb. 1991, 80(2), 104-7.
Griffin, G et al, J. Pharmacol. Exper. Ther., 292 (3), Mar. 2000, 886-894.
Stanley-Cary, C et al, Behav. Pharmacol., Feb. 2002, 13(1), 15-28.
Primary Examiner: Cook; Rebecca
Attorney, Agent or Firm: Roddy; Kenneth A.
Parent Case Text
CROSS REFERENCE TO RELATED APPLICATION
This application is a Continuation-In-Part of U.S. patent application Ser. No. 09/749,179, filed Dec. 26, 2000, now abandoned, which is a Continuation-In-Part of U.S. patent application Ser. No. 09/321,178, filed May 27, 1999, now abandoned.
Claims
1. A method of relieving a human patient of pain, discomfort and tissue inflammation associated with arthritis, bursitis, fibromyalgia, carpal tunnel syndrome, or gout, comprising the step of
topically applying to the skin of the patient a liquid cannabinoid liniment composition consisting of from about 97.5% to about 99.5% by weight of 70% isopropyl alcohol solution; and
from about 0.5% to about 2.5% by weight of a cannabinoid mixture extracted from the female plant Cannabis sativa L, in said isopropyl alcohol solution including in combination: 9-Tetrahydrocannabinol (delta-9-THC), 9-THC Propyl Analogue (THC-V), Cannabidiol (CBD), Cannabidiol Propyl Analogue (CBD-V), Cannabinol (CBN), Cannabichromene (CBC), Cannabichromene Propyl Analogue (CBC-V), Cannabigerol (CBG), cannabinoid terpenoids, and cannabinoid flavonoids; wherein
the constituents of said mixture are absorbed through the skin and interact with cannabinoid receptors in the body and tissues of the patient to produce therapeutic analgesic and anti-inflammatory effects without producing undesirable psychotropic side effects;
said Tetrehydrocannabinol (delta-9-THC) providing analgesic and anti-inflammatory effects, said Cannabidiol (CBD) providing potent antioxidant, neuroprotective and anti-inflammatory effects and reducing psychoactive effects of said Tetrahydrocannabinol (delta-9-THC), said Cannabichromene (CBC) providing sedative and analgesic effects, said Cannabigerol (CBG) providing sedative and anti-microbial effects, and said cannaboinoid terpenoids and cannabinoid flavonoids providing anti-inflammatory effects.
2. The method according to claim 1, wherein
said step of topically applying comprises spraying said cannabinoid liniment composition onto the skin in the area of discomfort or inflammation.
3. The method according to claim 1, wherein
said step of topically applying comprises applying a small amount of said cannabinoid liniment composition directly onto the skin in the area of discomfort or inflammation and rubbing it into the skin.
4. The method according to claim 1, wherein
said step of topically applying comprises applying said cannabinoid liniment over substantially the entire body of the patient, with the exception of the facial area.
5. A rapid-onset cannabinoid delivery topical liniment composition having analgesic and anti-inflammatory properties for relieving a human patient of pain, discomfort and tissue inflammation associated with arthritis, bursitis, fibromyalgia, carpal tunnel syndrome, or gout, consisting of:
from about 97.5% to about 99.5% by weight of 70% isopropyl alcohol solution; and
from about 0.5% to about 2.5% by weight of a cannabinoid mixture extracted from the female plant Cannabis sativa L, in said isopropyl alcohol solution including in combination: 9-Tetrahydrocannabinol (delta-9-THC), 9-THC Propyl Analogue (THC-V), Cannabidiol (CBD), Cannabidiol Propyl Analogue (CBD-V), Cannabinol (CBN), Cannabichromene (CBC), Cannabichromene Propyl Analogue (CBC-V), Cannabigerol (CBG), cannabinoid terpenoids, and cannabinoid flavonoids; wherein
the constituents of said mixture are absorbed through the skin and interact with cannabinoid receptors in the body and tissues of a human patient to produce therapeutic analgesic and anti-inflammatory effects without undesirable psychotropic side effects;
said Tetrehydrocannabinol (delta-9-THC) providing analgesic and anti-inflammatory effects, said Cannabidiol (CBD) providing potent antioxidant, neuroprotective and anti-inflammatory effects and reducing psychoactive effects of said Tetrahydrocannabinol (delta-9-THC), said Cannabichromene (CBC) providing sedative and analgesic effects, said Cannabigerol (CBG) providing sedative and anti-microbial effects, and said cannaboinoid terpenoids and cannabinoid flavonoids providing anti-inflammatory effects.
Description
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates generally to topical analgesic and anti-inflammation agents and more particularly to the use of a rapid-onset cannabinoid delivery topical liniment for the relief of pain and reduction in inflammation associated with such ailments as arthritis, bursitis, fibromyalgia, carpal tunnel syndrome, gout, and other muscular and joint aches and pains, and to the medicinal topical liniment preparation containing cannabinoids.
2. Description of Related Art
Analgesia is the medical term for pain relief. Analgesia is typified by a reduction in inflammation or swelling, common physiological responses to injury. It is known that injured tissue sprouts new nerve fibers with even greater sensitivity to pain, a condition known as hyperalgia.
Cannabis sativa, commonly known as marijuana, and its major psychoactive ingredient, delta-9-tetrahydrocannabinol (THC), and various other cannabis constituents, termed cannabinoids, cannabinoids have been widely studied.
In an early study submitted for publication in 1987 and published in 1988, titled "Transdermal Delivery of Tetrahydrocannabinol" (Touitou et al, International Journal of Pharmaceutics, 43 (1988): 9-15), research was conducted to establish the route of drug penetration, to determine the permeation coefficient through rat and human skin in vitro (in a test tube), and to measure blood concentration time patterns in vivo (in a living organism) for formulations containing synthetic delta-8-THC with and without oleic acid, with the final goal being the design of a transdermal delivery system.
In another early study submitted for publication in 1991 and published in 1991, titled "Localization of Molecules Penetrating Rat Skin In Vivo by Quantitative Autoradiography" (Fabin et al, International Journal of Pharmaceutics, 74 (1991): 59-65), tests were conducted to investigate the localization and penetration pathways of two lipophilic compounds, tetrahydrocannabinol (THC) and oleic acid (OA) through the skin of live rats by means of a quantitative autoradiography technique, and a further goal was to learn the effect of carriers on the drug distribution between the rat skin layers and appendages of the two compounds. One test used pure Delta-8 THC in three different carriers: (1) a carrier of polyethylene glycol (PEG), (2) a carrier of Transcutol (diethylene glycol monoethyl ether), and (3) a carrier mixture of 7 parts propylene glycol (PG) and 3 parts ethanol (EtOH). The result of the investigation showed that after 2 hrs, the highest skin penetration of THC was observed from the Transcutol (diethylene glycol monoethyl ether) carrier but no significant difference was seen in the concentration of THC in the epidermis and in the appendages in all three systems. After 24 hours, the Transcutol system delivered the highest THC concentration to the various layers of the skin, and with the 7 parts propylene glycol (PG) and 3 parts ethanol (EtOH) carrier, the highest concentration of THC was in the epidermis and the lowest was lower in the dermis. It was also shown that a penetration enhancing agent, such as oleic acid (OH) may effect the localization of THC in the various skin layers. The highest concentration of drug was found in the epidermis and appendages.
Both of these studies utilized delta-8-THC rather than delta-9-THC or naturally occurring cannabinoids extracted from female cannabis green leaves of the plant Cannabis sativa L. Neither study discloses, with any specificity, the ratio of the THC component relative to the carrier component or the concentration per unit volume of the THC component. Neither study discloses or suggests any analgesic and anti-inflammatory properties of the THC formulation.
MARINOL
c-ray
04-22-2006, 12:12 PM
DESCRIPTION OF PREFERRED EMBODIMENTS
The following examples describe several formulations and methods of preparation of a preferred rapid-onset cannabinoid delivery topical liniment compounded for particular use as an analgesic and anti-inflammation agent. These examples are provided for illustrative purposes only and should not be construed as limiting the scope of the invention. Many variations and applications, which do not depart from the scope and spirit of the present invention, will be apparent to those skilled in the art. All such modifications are within the intended scope of this invention.
A monohydric alcohol is used in the preparation of the present liniment composition, which facilitates extraction of the hydrophobic cannabinoids such as 9-Tetrahydrocannabinol (delta-9-THC). In a preferred embodiment, a 70% isopropyl or denatured ethyl alcohol is used. However, it should be understood that other alcohols may be used such as N-propyl alcohol and cetyl alcohol.
Preparation 1
In one formulation, the topical analgesic and anti-inflammation liniment composition is prepared by crushing from about ⅓ oz to about 1.0 oz (dry weight) of female cannabis green leaves of the plant Cannabis sativa L. The leaves contain hundreds of chemicals and scores of cannabinoids, including: 9-Tetrahydrocannabinol (delta-9-THC), 9-THC Propyl Analogue (THC-V), Cannabidiol (CBD), Cannabidiol Propyl Analogue (CBD-V), Cannabinol (CBN), Cannabichromene (CBC), Cannabichromene Propyl Analogue (CBC-V), Cannabigerol (CBG), many terpenoids and several flavonoids. The concentration of the psychoactive 9-Tetrahydrocannabinol (delta-9-THC) in the plant leaves may range from about 1% to about 15% per unit of volume with a concentration of over 10% being preferred.
The crushed leaves are then placed into a mixing container. About 16 fluid oz of a 70% alcohol solution is poured into the container and mixed with the crushed leaves. The container is then tightly capped and the mixture is allowed to soak or steep in the container for about 15 to 30 days without opening the container. The container may be gently shaken every 1 to 2 days during the steeping period. After the 15 to 30 day steeping period, the mixture is strained through a strainer to remove any solids from the mixture. The solids are discarded and the liquid is poured into a dispensing container or bottle, which is then capped, and the topical liniment is ready for use.
In Preparation 1, the ratio of the dry leaves to alcohol before steeping and extraction of the cannabinoid component, may be in the range of from about 2.0% to about 7.0% by weight of the crushed leaves to from about 93% to about 98.0% by weight of the monohydric alcohol solution. After steeping and extraction, the final composition contains from about 0.5% to about 2.0% by weight of the cannabinoid component, with about 1.0% by weight of the cannabinoid component being preferred.
Preparation 2
In a second formulation, the topical analgesic and anti-inflammation liniment composition is prepared the same as Preparation 1, except that the ratio of the dry leaves to alcohol before steeping and extraction of the cannabinoid component, may be in the range of from about 3.0% to about 9.0% by weight of the crushed leaves to from about 91% to about 97.0% by weight of the monohydric alcohol solution. After steeping and extraction, the final composition contains from about 0.9% to about 2.5% by weight of the extracted cannabinoid component, with about 1.3% by weight of the cannabinoid component being preferred.
The time period for soaking or steeping the mixtures of the formulations may be shortened by heating the mixture at a temperature in the range of from about 85
skeeter
04-22-2006, 02:39 PM
Great job finding the info..C-Ray:good: I was thinking people would think I'd totally lost it, when I first posted in this thread...
This really works, or it does for me... I give the mix away to older people I know, and it works for them too.. I have personally seen people who can't hardly walk use it, and with a few days..I can see them with a smile on their face, and ready to get up, and do something..
I guess these are the topical solutions for pain the big pharmies, don't want all of us to know about:p
ViRedd
05-03-2006, 10:12 PM
While the old CW was up and running, I posted an account of a woman I know who, now in her late 80's, suffers from acute arthritis. She gets cannabis leaves from her Mexican gardner who brings them back from his trips to see his family in Mexico. She soaks the leaves in rubbing alcohol for a week, wrings the leaves out, then takes a swab of cotton, soaks it in the liquid and rubs it over the affected areas of her hands. She says the pain disappears almost immediately. She told her doctor about this and he said: "Oh yes, I've heard of that. This is what the poor people in Mexico do. Just be careful and don't get caught." What a shame that a person like she has to worry about getting "caught."
Vi
vBulletin® v3.7.3, Copyright ©2000-2012, Jelsoft Enterprises Ltd.